0A4C Stock Chart & Stats
$2.89
$0.00(0.00%)
At close: 4:00 PM EDT
$2.89
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.89 - $5.87
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$632.18M
Enterprise Value$273.45
Total Cash (Recent Filing)$326.32M
Total Debt (Recent Filing)$35.75M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 10, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding194,517,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.50Price Target Upside574.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$1.88K
Bulls Say, Bears Say
Bulls Say
MASH Phase III AdvancementStarting a global Phase III MASH program across about 300 sites materially advances pemvidutide toward a registrational outcome. The broad international design and stated 18–24-month enrollment target create a defined development path, although commercialization remains several years away.
Cash Runway And Low LeverageCash of $519M and management’s statement that it funds PERFORMA through the 52-week readout provide meaningful near-term financing visibility. Low debt-to-equity and higher equity and assets further reduce solvency pressure while the company executes its lead program.
Positive AUD Clinical DifferentiationRECLAIM’s multiple positive efficacy signals support pemvidutide’s potential differentiation in AUD, including behavioral outcomes, objective PEth improvement, and weight loss. A profile spanning drinking reduction and metabolic benefit could broaden clinical utility if confirmed in pivotal development.
Bears Say
Minimal Revenue And Persistent LossesAltimmune has not yet established recurring product revenue, while its cost base remains far ahead of sales and produces substantial losses. This leaves fundamental performance dependent on successful clinical development and future financing rather than an operating business that currently funds itself.
Sustained Cash BurnSustained operating and free-cash-flow deficits show that research and development spending is consuming capital without being offset by revenue. Continued burn can shorten financial flexibility over time and increases the importance of disciplined spending, successful trials, and access to additional capital.
AUD Phase III Funding GapThe lead MASH program has stated funding visibility, but a potential AUD Phase III would require additional financing beyond the current runway. Management is pursuing royalties, debt, or partnerships, yet those sources are not guaranteed and could affect the pace or scope of expansion.
Altimmune News
0A4C FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest share price was $2.89 and its highest was $5.87 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $632.18M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 10, 2026 which is in 51 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 12, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc does not currently pay dividends.
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.14.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 194,517,700 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in GB:0A4C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (574.74% Upside)
$19.50 (574.74% Upside)
Blogger Sentiment
Bullish
GB:0A4C Sentiment 89%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Altimmune Inc
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
0A4C Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all GB:0A4C earnings summaries0A4C Stock 12 Month Forecast
Average Price Target
$19.50
▲(574.74% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―